trending Market Intelligence /marketintelligence/en/news-insights/trending/6N7MTYeneoZRd1wEKIuIgQ2 content esgSubNav
In This List

Endo International settles opioid charges in 2 Ohio counties for $10M

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Endo International settles opioid charges in 2 Ohio counties for $10M

Endo International PLC has finalized the settlement of two Ohio lawsuits regarding its opioid marketing activities and will pay a total of $10 million to Ohio's Summit and Cuyahoga counties.

Under the settlement, Dublin-based Endo will also provide up to $1 million of its Vasostrict and Adrenalin products to both the counties free of charge.

Cuyahoga County will receive $6.2 million in cash and up to $620,000 of Vasostrict or Adrenalin, while Summit County will receive $3.8 million in cash and up to $380,000 of Vasostrict or Adrenalin.

Dublin-based Allergan PLC has settled with the state of Ohio for $5 million.

A U.S. District Court judge in Ohio has ordered that makers of opioids must face an October trial to determine whether the companies' marketing practices contributed to the crisis of painkiller addiction. The defendants include Endo, pharmaceutical giant Johnson & Johnson, Purdue Pharma LP, Allergan, Mallinckrodt PLC and Teva Pharmaceutical Industries Ltd.

Johnson & Johnson is appealing an Aug. 26 ruling by a judge in Oklahoma that ordered the company to pay $572 million to the state for its role in the opioid epidemic.

OxyContin maker Purdue has been reported to be closing down on a possible settlement in the range of $10 billion to $12 billion for all of their opioid cases.